← Eichor
Condition: Brca Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Brca Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer
Phase N/A · 2 location(s) · Santa Chiara Hospital · NCT06783127Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1 · 2 location(s) · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · NCT06666270The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.
Phase N/A · 1 location(s) · Institute of Cancer Research, United Kingdom · NCT05097274Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
Phase 2 · 1 location(s) · Fudan University · NCT06516289Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2 · 3 location(s) · Okayama University · NCT05485766A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Su
Phase 1 · 1 location(s) · Boryung Pharmaceutical Co., Ltd · NCT07069335BRCA Mutation Carriers' Platform a Multicenter Study
Phase N/A · 40 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07253051Prediction of Germline BRCA 1/2 Genes From Healthy Ovaries
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT05769517Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation
Phase N/A · 1 location(s) · Institut Paoli-Calmettes · NCT03667417Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene
NA · 1 location(s) · CHU de Quebec-Universite Laval · NCT06817694Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands
Phase N/A · 1 location(s) · Peking University Third Hospital · NCT07039552Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
Phase 1 · 1 location(s) · Varun Monga, MBBS · NCT06177171MEASUREMENT OF CIRCULATING MUTATION BURDEN
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06792721Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metas
Phase N/A · 1 location(s) · European Institute of Oncology · NCT06762483Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Phase 1 · 1 location(s) · Daewoong Pharmaceutical Co. LTD. · NCT07371104Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT05576389A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Phase 1/Phase 2 · 14 location(s) · 858 Therapeutics, Inc. · NCT06395519A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate
Phase 3 · 342 location(s) · AstraZeneca · NCT06952803Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breas
Phase N/A · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT00823654Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04090567Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
Phase N/A · 9 location(s) · Lund University · NCT02306096A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)
NA · 1 location(s) · Vasileios Kalles · NCT07292246Registry of Subjects at Risk of Pancreatic Cancer
Phase N/A · 4 location(s) · Associazione Italiana per lo Studio del Pancreas · NCT04095195Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Acerand Therapeutics (Shanghai) Limited · NCT06380660The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer
NA · 6 location(s) · Institut Claudius Regaud · NCT06588322Population Based Germline Testing for Early Detection and Prevention of Cancer
NA · 1 location(s) · Queen Mary University of London · NCT07498829
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.